Biocon Ltd (Biocon) offers biopharmaceuticals, generic active pharmaceutical ingredients (APIs), and research services. The company has an operational presence in the US, Canada, Brazil, the UAE, Malaysia, the Philippines, Morocco, the UK, Ireland, Switzerland, Germany, France, Greece, and India. The company serves over 750 pharma companies across more than 100 countries. It had 11 manufacturing units and 182 products in its portfolio. It also had a manufacturing capacity of 900 MT per year (APIs) under Biocon Ltd; more than 300 KL per year under Biocon Biologics Ltd; 50 KL per year under Sygene for drug substances. It also had a manufacturing capacity of 880 million units per year under BL and more than 100 million units per year under BBL for drug products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biocon has strategically invested in research and development to drive innovation and enhance its global presence. The company focuses on developing generics, biosimilars, and novel therapies, with a primary emphasis on diabetes, oncology, and immunology. Biocon Ltd leverages cutting-edge technologies, specialized knowledge, and strategic collaborations to create affordable therapeutic solutions. The company has also integrated AI, machine learning, and predictive modeling into its R&D processes to accelerate product development and improve decision-making. Additionally, Biocon is committed to reducing its ecological footprint and improving environmental efficiency through its R&D activities. The R&D units of the Biocon Group include Biocon Ltd, Biocon Biologics, and Syngene International Ltd. Biocon Ltd focuses on developing synthetic and fermentation-based generic small molecules, as well as innovative technologies in API process development. Biocon Biologics is dedicated to building biosimilars' R&D and manufacturing capabilities. Syngene, as a contract research, development, and manufacturing organization, offers integrated services from drug discovery to commercial manufacturing, enhancing speed to market and cost efficiency. Major technology alliances include partnerships with IBAB, Bengaluru, and IIT Madras for the development of high-performance strains and genome-scale models, respectively. In FY2025, the company spent INR8,585 million on R&D, which as a percentage of revenue, stood at 5.2% and decreased 26.1% YoY. As of March 2025, under Generics, the company had 326 patents, 111 active patents, five patents obtained, six patents filed, 26 trademarks obtained, 475 total trademarks, and 30 trademarks filed. Biosimilars had 400 patents, 311 active patents, eight patents obtained, three patents filed, 107 trademarks obtained, 2,323 trademarks, and 120 trademarks filed. Furthermore, Novels had 792 patents, 171 active patents, eight patents obtained, seven patents filed, one trademark obtained, 14 total trademarks, and one trademark filed.